BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25077564)

  • 1. Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.
    Riccardo F; Arigoni M; Buson G; Zago E; Iezzi M; Longo D; Carrara M; Fiore A; Nuzzo S; Bicciato S; Nanni P; Landuzzi L; Cavallo F; Calogero R; Quaglino E
    BMC Genomics; 2014; 15 Suppl 3(Suppl 3):S1. PubMed ID: 25077564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
    Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
    Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
    Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
    Konishi T; Huang CL; Adachi M; Taki T; Inufusa H; Kodama K; Kohno N; Miyake M
    Int J Oncol; 2000 Mar; 16(3):501-11. PubMed ID: 10675482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
    Wang M; Li P; Wan R; Liu X
    Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
    Duan XY; Wang W; Wang JS; Shang J; Gao JG; Guo YM
    BMC Cancer; 2013 Nov; 13():546. PubMed ID: 24237755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.
    Durrans A; Gao D; Gupta R; Fischer KR; Choi H; El Rayes T; Ryu S; Nasar A; Spinelli CF; Andrews W; Elemento O; Nolan D; Stiles B; Rafii S; Narula N; Davuluri R; Altorki NK; Mittal V
    PLoS One; 2015; 10(6):e0129123. PubMed ID: 26046767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
    Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
    J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer.
    Liu J; Lin Y; Yang H; Deng Q; Chen G; He J
    Tumour Biol; 2011 Dec; 32(6):1113-21. PubMed ID: 21779982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel subpopulation of Caspase-4 positive non-small cell lung Cancer patients.
    Terlizzi M; Colarusso C; De Rosa I; Somma P; Curcio C; Aquino RP; Panico L; Salvi R; Zito Marino F; Botti G; Pinto A; Sorrentino R
    J Exp Clin Cancer Res; 2020 Nov; 39(1):242. PubMed ID: 33187551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
    Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
    Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
    Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
    J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.
    Brannan JM; Dong W; Prudkin L; Behrens C; Lotan R; Bekele BN; Wistuba I; Johnson FM
    Clin Cancer Res; 2009 Jul; 15(13):4423-30. PubMed ID: 19531623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
    Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
    PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.